| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS44041843 | HTLV-1 | ENSG00000140443.15 | protein_coding | IGF1R | Yes | No | 3480 | C9J5X1 P08069 |
| TVIS44047281 | HTLV-1 | ENSG00000140443.15 | protein_coding | IGF1R | Yes | No | 3480 | C9J5X1 P08069 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | IGF1R |
|---|---|
| DrugBank ID | DB16637 |
| Drug Name | KW-2450 free base |
| Target ID | BE0000858 |
| UniProt ID | P08069 |
| Regulation Type | inhibitor |
| PubMed IDs | 30083253 |
| Citations | Umehara H, Maekawa Y, Koizumi F, Shimizu M, Ota T, Fouad TM, Willey J, Kaito H, Shiraishi N, Nakashima D, Akinaga S, Ueno NT: Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole. Ther Adv Med Oncol. 2018 Jul 30;10:1758835918786858. doi: 10.1177/1758835918786858. eCollection 2018. |
| Groups | Experimental |
| Direct Classification | |
| SMILES | CC1=C(SC=C1)C(=O)NC1=CC(CN2CCN(CC2)C(=O)CO)=CC=C1C=CC1=NNC2=CC=CC=C12 |
| Pathways | |
| PharmGKB | |
| ChEMBL |
